GSK Gains T-Cell Vaccine Tech With €250 Million Okairos Acquisition
This article was originally published in The Pink Sheet Daily
The British pharma has done the biggest takeout of a private, clinical-stage European biotech so far this year. It is focused on a Phase I RSV vaccine and a T-cell stimulating technology. As for VCs, they have nabbed roughly a 10x return on their invested capital.